Two newly published articles throw a greater spotlight on a decision -- now before the U.S. Food and Drug Administration (FDA) -- that would potentially bring a new drug therapy to Alzheimer's patients for the first time in nearly 20 years.

It’s estimated that one in nine people older than 65 in Nevada live with Alzheimer’s disease. The state also ranks as the 3rd fastest growing dementia population in the country.

A new study endeavor will explore US Food and Drug Administration (FDA) approved medications for efficacy in Alzheimer disease.

In the US, about 6.2 million people have Alzheimer's disease. About 70% experience agitation — extreme emotional distress that can manifest as resisting care, shouting, or becoming physically violent — and 40% have symptoms severe enough to require treatment, Dr. Jeffrey Cummings told Insider. But there isn't a single approved drug to treat agitation in people with Alzheimer's.

Last week, AB Science reported successful results from a phase IIb/III clinical trial testing its drug masitinib in patients with mild to moderate symptoms of Alzheimer’s.

AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.

AB Science SA (NYSE Euronext – FR0010557264 – AB) will host a live webcast on December 17, 2020 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in Alzheimer’s Disease.

A little more than a century ago, a German psychiatrist and neuropathologist by the name of Aloysius Alzheimer, MD, first described the pathology and symptoms of a disease known as presenile dementia at a 1906 meeting of the Southwest German Psychiatrists.